The Effect of Imatinib Mesylate for Newly Diagnosed Philadelphia Chromosome-Positive, Chronic-Phase Myeloid Leukemia in Sub-Saharan African Patients: The Experience of Côte d'Ivoire

Table 2

Detailed cytogenetic response of 17 CML patients with additional chromosomal abnormalities prior to imatinib therapy.

Patient no.	Cytogenetic analysis
(1)	46,XX, t(9;22)(q34;q11)[11] / 45-46,idem, dup (14)(q22;q32)[5]
(2)	46, XY, t(9; 22) (q34; q11) [20]/46, idem, del (12) (p12) [12]
(3)	46,XX, t(9;22)(q34;q11)[9]/47,XX, idem,+8[11]
(4)	46,XY, t(3;13)(p25;q14),t(9;22)(q34;q11)
	[28]/52,idem,+6,+7,+8,+19,+21,+der(22),t(9;22)(q34;q11)[12]
(5)	46, XY, del(3)(p12p14), t(9;22)(q34;q11)[5]/46,XY, t(9;22)^′ q34;q11)[31]
(6)	46, XY, t(9;10;22)(q34;p14;q11)[15]/ 46,XY, t(9;10;22) (q34;p14;q11),del(13)(q21)[2]/
	47, XY, t(9;10;22)(q34;p14;q11),+mar1[3]
(7)	46,XX, t(9;22)(q34;q12)[29] / 46,idem, t(4;11)(q13;p12)[11]
(8)	46,XY,t(9;22)(q34;q11)[14]/47,idem,+8[11]
(9)	46,XX,t(9;22)(q34;q11),add(13)(p11),add(20)(p13)[23]
(10)	46, XY, t(9;22) ([16]/46,idem,der(12)t(12;14)(q10;q10),add(13)(p11.2),-14,- mar[4]
(11)	46, XY, t(9;22)[12]/46, XY, der(9)t(9;22),der(22q)[7]/ 47, XY, t(9;22), der(22)t(9;22)[11]
(12)	46, XY, t(9;22),-17,add(19)(q13.4),- mar[19]/46,XY, t(9;22),- 17,add(19)(q13.4)[11]
(14)	47 XY,+8,t(9;22)(q34;q11)[3] /46,XY,t(9;22)(q34;q11)[23]
(15)	46, XY,t(9;22)[8]/46,idem,add(1)(p36.3)[12]
(16)	46, XY, add(2)(p25),t(9;22)(q34;q11)[6] /46,XY,t(9;22)(q34;q11)[43]
(17)	46,XY,t(2;9;22)(q15;q34;d11)[28]